<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40969554</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2235-2988</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in cellular and infection microbiology</Title><ISOAbbreviation>Front Cell Infect Microbiol</ISOAbbreviation></Journal><ArticleTitle>Efficacy of thymosin &#x3b1;1 for sepsis: a systematic review and meta-analysis of randomized controlled trials.</ArticleTitle><Pagination><StartPage>1673959</StartPage><MedlinePgn>1673959</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1673959</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fcimb.2025.1673959</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Despite advances in understanding sepsis pathophysiology and extensive research, few treatments effectively target its underlying immune dysfunction. Thymosin &#x3b1;1 (T&#x3b1;1) shows promise as an immunomodulator, but its impact on sepsis remains unclear.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A search strategy was designed to include any prospective clinical studies using T&#x3b1;1 for assessing 28-day mortality in patients with sepsis, excluding combination therapy studies. We conducted trial sequential analysis (TSA) to assess the robustness of meta-analyses findings. Heterogeneity of treatment effects (HTE) was conducted based on individual data from two multicenter randomized clinical trials (RCTs), with result credibility assessed through the instrument to assess the credibility of effect modification analyses (ICEMAN).</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Out of 3003 identified studies, 11 RCTs met the inclusion criteria (967 patients in T&#x3b1;1 group and 960 patients in control group). The comprehensive meta-analysis demonstrated a significant reduction in 28-day mortality associated with T&#x3b1;1 administration (OR 0.73, 95%CI: 0.59-0.90, <i>P</i> = 0.003). Nonetheless, analyses of high-quality (OR 0.82, 95%CI: 0.65-1.03, <i>P</i> = 0.09) and multi-center (OR 0.86, 95%CI: 0.68-1.08, <i>P</i> = 0.20) subgroups did not reveal a mortality benefit. The HTE analysis of multiple subgroups in two large RCTs (representing 75% of the total patients) showed heterogeneity. Potential benefits were noted in subgroups of cancer (moderate credibility), diabetes (low credibility), and coronary heart disease (low credibility). Furthermore, the trial sequential analysis (TSA) suggests that the current sample size is inadequate.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">T&#x3b1;1 has the potential to decrease 28-day mortality rates in patients with sepsis; however, it is crucial to recognize that its efficacy differs among various subgroups. These observations underscore the significance of personalized immunotherapy strategies in forthcoming clinical trials.</AbstractText><AbstractText Label="SYSTEMATIC REVIEW REGISTRATION" NlmCategory="UNASSIGNED">https://www.crd.york.ac.uk/prospero/, identifier CRD42024628937.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Gu, Zhou, Nie, Wang, Liang, Liao, Wen, Guan, Chen, Wu and Pei.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Gu</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong,&#xa0;China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Clinical Research Center for Critical Care Medicine, Guangzhou, Guangdong,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhou</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong,&#xa0;China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Clinical Research Center for Critical Care Medicine, Guangzhou, Guangdong,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Nie</LastName><ForeName>Yao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong,&#xa0;China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Clinical Research Center for Critical Care Medicine, Guangzhou, Guangdong,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Luhao</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong,&#xa0;China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Clinical Research Center for Critical Care Medicine, Guangzhou, Guangdong,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Liqun</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong,&#xa0;China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Clinical Research Center for Critical Care Medicine, Guangzhou, Guangdong,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Zihuai</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong,&#xa0;China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Clinical Research Center for Critical Care Medicine, Guangzhou, Guangdong,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Jingyi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong,&#xa0;China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Clinical Research Center for Critical Care Medicine, Guangzhou, Guangdong,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guan</LastName><ForeName>Xiangdong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong,&#xa0;China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Clinical Research Center for Critical Care Medicine, Guangzhou, Guangdong,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Minying</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong,&#xa0;China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Clinical Research Center for Critical Care Medicine, Guangzhou, Guangdong,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jianfeng</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong,&#xa0;China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Clinical Research Center for Critical Care Medicine, Guangzhou, Guangdong,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pei</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong,&#xa0;China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Clinical Research Center for Critical Care Medicine, Guangzhou, Guangdong,&#xa0;China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Cell Infect Microbiol</MedlineTA><NlmUniqueID>101585359</NlmUniqueID><ISSNLinking>2235-2988</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>W0B22ISQ1C</RegistryNumber><NameOfSubstance UI="D000077596">Thymalfasin</NameOfSubstance></Chemical><Chemical><RegistryNumber>61512-21-8</RegistryNumber><NameOfSubstance UI="D013947">Thymosin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="Y">Sepsis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077596" MajorTopicYN="Y">Thymalfasin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013947" MajorTopicYN="Y">Thymosin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">heterogeneity of treatment effects</Keyword><Keyword MajorTopicYN="N">personalized immunotherapy</Keyword><Keyword MajorTopicYN="N">sepsis</Keyword><Keyword MajorTopicYN="N">thymosin &#x3b1;1</Keyword><Keyword MajorTopicYN="N">trial sequential analysis</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>5</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40969554</ArticleId><ArticleId IdType="pmc">PMC12440967</ArticleId><ArticleId IdType="doi">10.3389/fcimb.2025.1673959</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aynekulu Mersha D. G., Fromme S. E., van Boven F., Arteaga-Henriquez G., Wijkhuijs A., van der Ent M., et al. (2025). Indications for an antidepressive effect of thymosin alpha-1 in a small open-label proof of concept study in common variable immune deficiency patients with depression. Brain Behav. Immun. Health 43, 100934. doi:&#xa0; 10.1016/j.bbih.2024.100934, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbih.2024.100934</ArticleId><ArticleId IdType="pmc">PMC11762651</ArticleId><ArticleId IdType="pubmed">39867848</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J. (2007). Effects of thymosin-alpha1 on cell immunity function in patients with septic shock. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 19, 153&#x2013;155. doi:&#xa0; 10.3760/j.issn:1003-0603.2007.03.008, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/j.issn:1003-0603.2007.03.008</ArticleId><ArticleId IdType="pubmed">17376268</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan X., Lin T., Xu K., Yin Z., Huang H., Dong W., et al. (2012). Laparoendoscopic single-site nephrectomy compared with conventional laparoscopic nephrectomy: a systematic review and meta-analysis of comparative studies. Eur. Urol 62, 601&#x2013;612. doi:&#xa0; 10.1016/j.eururo.2012.05.055, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2012.05.055</ArticleId><ArticleId IdType="pubmed">22704730</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Z., Shi Q., Fan Y., Wang Q., Yin W. (2016). Ulinastatin and/or thymosin alpha1 for severe sepsis: A systematic review and meta-analysis. J. Trauma Acute Care Surg. 80, 335&#x2013;340. doi:&#xa0; 10.1016/j.intimp.2015.10.026, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2015.10.026</ArticleId><ArticleId IdType="pubmed">26517783</ArticleId></ArticleIdList></Reference><Reference><Citation>Frydrych L. M., Fattahi F., He K., Ward P. A., Delano M. J. (2017). Diabetes and sepsis: risk, recurrence, and ruination. Front. Endocrinol. (Lausanne) 8, 271. doi:&#xa0; 10.3389/fendo.2017.00271, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2017.00271</ArticleId><ArticleId IdType="pmc">PMC5670360</ArticleId><ArticleId IdType="pubmed">29163354</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgiou P., Tan E., Gouvas N., Antoniou A., Brown G., Nicholls R. J., et al. (2009). Extended lymphadenectomy versus conventional surgery for rectal cancer: a meta-analysis. Lancet Oncol. 10, 1053&#x2013;1062. doi:&#xa0; 10.1016/s1470-2045(09)70224-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1470-2045(09)70224-4</ArticleId><ArticleId IdType="pubmed">19767239</ArticleId></ArticleIdList></Reference><Reference><Citation>Gui C., Ai Y., Zhang L. (2012). Effectiveness of thymosin &#x3b1;1 therapy and its effects on immune function in the patients with sepsis. Chin. J. Crit. Care Med. 32, 255&#x2013;258. doi:&#xa0; 10.3969/j.issn.1002-1949.2012.03.018</Citation><ArticleIdList><ArticleId IdType="doi">10.3969/j.issn.1002-1949.2012.03.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins J. P., Altman D. G., G&#xf8;tzsche P. C., J&#xfc;ni P., Moher D., Oxman A. D., et al. (2011). The Cochrane Collaboration&#x2019;s tool for assessing risk of bias in randomised trials. Bmj 343, d5928. doi:&#xa0; 10.1136/bmj.d5928, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d5928</ArticleId><ArticleId IdType="pmc">PMC3196245</ArticleId><ArticleId IdType="pubmed">22008217</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins J. P., Thompson S. G., Deeks J. J., Altman D. G. (2003). Measuring inconsistency in meta-analyses. Bmj 327, 557&#x2013;560. doi:&#xa0; 10.1136/bmj.327.7414.557, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.327.7414.557</ArticleId><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotchkiss R. S., Opal S. M. (2020). Activating immunity to fight a foe - A new path. N Engl. J. Med. 382, 1270&#x2013;1272. doi:&#xa0; 10.1056/NEJMcibr1917242, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcibr1917242</ArticleId><ArticleId IdType="pmc">PMC8025910</ArticleId><ArticleId IdType="pubmed">32212525</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu H., Huang S., Zhu Z., Xiong F., Liu W. (2016). The clinical efficiency analysis of thymosin-&#x3b1;1 in treating sepsis. Chin. J. Crit. Care Med. 36, 397&#x2013;400. doi:&#xa0; 10.3969/j.issn.1002-1949.2016.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.3969/j.issn.1002-1949.2016.05.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue S., Suzuki-Utsunomiya K., Okada Y., Taira T., Iida Y., Miura N., et al. (2013). Reduction of immunocompetent T cells followed by prolonged lymphopenia in severe sepsis in the elderly. Crit. Care Med. 41, 810&#x2013;819. doi:&#xa0; 10.1097/CCM.0b013e318274645f, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e318274645f</ArticleId><ArticleId IdType="pubmed">23328259</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalil A. C., Povoa P., Leone M. (2025). Subphenotypes and phenotypes to resolve sepsis heterogeneity: hype or hope? Intensive Care Med. 51, 582&#x2013;584. doi:&#xa0; 10.1007/s00134-025-07828-x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-025-07828-x</ArticleId><ArticleId IdType="pubmed">40047867</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C., Bo L., Liu Q., Jin F. (2015). Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis. Int. J. Infect. Dis. 33, 90&#x2013;96. doi:&#xa0; 10.1016/j.ijid.2014.12.032, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2014.12.032</ArticleId><ArticleId IdType="pubmed">25532482</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H. Y. (2007). Clinical trial with a new immunomodulatory strategy: treatment of severe sepsis with Ulinastatin and Maipuxin. Natl. Med. J. China 87, 451&#x2013;457. doi:&#xa0; 10.3760/j:issn:0376-2491.2007.07.005, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/j:issn:0376-2491.2007.07.005</ArticleId><ArticleId IdType="pubmed">17459221</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Pang Y., Hu Z., Wu M., Wang C., Feng Z., et al. (2020). Thymosin alpha 1 (Talpha1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells. Clin. Infect. Dis. 71 (16), 2150&#x2013;2157. doi:&#xa0; 10.1093/cid/ciaa630, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa630</ArticleId><ArticleId IdType="pmc">PMC7314217</ArticleId><ArticleId IdType="pubmed">32442287</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H., Qian S. C., Zhang Y. Y., Tang C. B., Yue H. H., Fan G. L., et al. (2025). Effect of thymosin alpha1 on Immune response and organ function in acute aortic dissection surgery: PANDA II trial protocol. Future Cardiol. 21, 447&#x2013;454. doi:&#xa0; 10.1080/14796678.2025.2505401, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14796678.2025.2505401</ArticleId><ArticleId IdType="pmc">PMC12143670</ArticleId><ArticleId IdType="pubmed">40367062</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F., Wang H. M., Wang T., Zhang Y. M., Zhu X. (2016). The efficacy of thymosin alpha1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials. BMC Infect. Dis. 16, 488. doi:&#xa0; 10.1186/s12879-016-1823-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-016-1823-5</ArticleId><ArticleId IdType="pmc">PMC5025565</ArticleId><ArticleId IdType="pubmed">27633969</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D., Yu Z., Yin J., Chen Y., Zhang H., Xin F., et al. (2016). Effect of ulinastatin combined with thymosin alpha1 on sepsis: A systematic review and meta-analysis of Chinese and Indian patients. J. Crit. Care 39, 259&#x2013;266. doi:&#xa0; 10.1016/j.jcrc.2016.12.013, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2016.12.013</ArticleId><ArticleId IdType="pubmed">28069319</ArticleId></ArticleIdList></Reference><Reference><Citation>Matteucci C., Minutolo A., Balestrieri E., Petrone V., Fanelli M., Malagnino V., et al. (2021). Thymosin alpha 1 mitigates cytokine storm in blood cells from coronavirus disease 2019 patients. Open Forum Infect. Dis. 8, ofaa588. doi:&#xa0; 10.1093/ofid/ofaa588, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofaa588</ArticleId><ArticleId IdType="pmc">PMC7798699</ArticleId><ArticleId IdType="pubmed">33506065</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer N. J., Prescott H. C. (2024). Sepsis and septic shock. N Engl. J. Med. 391, 2133&#x2013;2146. doi:&#xa0; 10.1056/NEJMra2403213, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra2403213</ArticleId><ArticleId IdType="pubmed">39774315</ArticleId></ArticleIdList></Reference><Reference><Citation>Mian M. O., Paradis P., Schiffrin E. L. (2014). Innate immunity in hypertension. Curr. Hypertens. Rep. 16, 413. doi:&#xa0; 10.1007/s11906-013-0413-9, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11906-013-0413-9</ArticleId><ArticleId IdType="pubmed">24407446</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikolajczyk T. P., Guzik T. J. (2019). Adaptive immunity in hypertension. Curr. Hypertens. Rep. 21, 68. doi:&#xa0; 10.1007/s11906-019-0971-6, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11906-019-0971-6</ArticleId><ArticleId IdType="pmc">PMC6647517</ArticleId><ArticleId IdType="pubmed">31321561</ArticleId></ArticleIdList></Reference><Reference><Citation>Page M. J., McKenzie J. E., Bossuyt P. M., Boutron I., Hoffmann T. C., Mulrow C. D., et al. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71. doi:&#xa0; 10.1136/bmj.n71, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Pei F., Gu B., Miao S. M., Guan X. D., Wu J. F. (2024). Clinical practice of sepsis-induced immunosuppression: Current immunotherapy and future options. Chin. J. Traumatol 27, 63&#x2013;70. doi:&#xa0; 10.1016/j.cjtee.2023.11.001, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cjtee.2023.11.001</ArticleId><ArticleId IdType="pmc">PMC11075145</ArticleId><ArticleId IdType="pubmed">38040590</ArticleId></ArticleIdList></Reference><Reference><Citation>Pei F., Guan X., Wu J. (2018). Thymosin alpha 1 treatment for patients with sepsis. Expert Opin. Biol. Ther. 18, 71&#x2013;76. doi:&#xa0; 10.1080/14712598.2018.1484104, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14712598.2018.1484104</ArticleId><ArticleId IdType="pubmed">30063866</ArticleId></ArticleIdList></Reference><Reference><Citation>Pei F., Nie Y., Si X., Jiang Z., Guan X., Chen J., et al. (2017). Thymosin alpha 1 reduces the expression of PD-L1 on monocyte of septic patients. J. Trop. Med. 17, 289&#x2013;292+310. doi:&#xa0; 10.3969/j.issn.1672-3619.2017.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.3969/j.issn.1672-3619.2017.03.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Pene F., Pickkers P., Hotchkiss R. S. (2016). Is this critically ill patient immunocompromised? Intensive Care Med. 42, 1051&#x2013;1054. doi:&#xa0; 10.1007/s00134-015-4161-y, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-015-4161-y</ArticleId><ArticleId IdType="pmc">PMC7095223</ArticleId><ArticleId IdType="pubmed">26630877</ArticleId></ArticleIdList></Reference><Reference><Citation>Romani L., Bistoni F., Gaziano R., Bozza S., Montagnoli C., Perruccio K., et al. (2004). Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 103, 4232&#x2013;4239. doi:&#xa0; 10.1182/blood-2003-11-4036, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2003-11-4036</ArticleId><ArticleId IdType="pubmed">14982877</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudd K. E., Johnson S. C., Agesa K. M., Shackelford K. A., Tsoi D., Kievlan D. R., et al. (2020). Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet 395, 200&#x2013;211. doi:&#xa0; 10.1016/s0140-6736(19)32989-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(19)32989-7</ArticleId><ArticleId IdType="pmc">PMC6970225</ArticleId><ArticleId IdType="pubmed">31954465</ArticleId></ArticleIdList></Reference><Reference><Citation>Schandelmaier S., Briel M., Varadhan R., Schmid C. H., Devasenapathy N., Hayward R. A., et al. (2020). Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. Cmaj 192, E901&#x2013;e906. doi:&#xa0; 10.1503/cmaj.200077, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.200077</ArticleId><ArticleId IdType="pmc">PMC7829020</ArticleId><ArticleId IdType="pubmed">32778601</ArticleId></ArticleIdList></Reference><Reference><Citation>Serafino A., Pierimarchi P., Pica F., Andreola F., Gaziano R., Moroni N., et al. (2012). Thymosin &#x3b1;1 as a stimulatory agent of innate cell-mediated immune response. Ann. N Y Acad. Sci. 1270, 13&#x2013;20. doi:&#xa0; 10.1111/j.1749-6632.2012.06707.x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2012.06707.x</ArticleId><ArticleId IdType="pubmed">23050812</ArticleId></ArticleIdList></Reference><Reference><Citation>Seymour C. W., Kennedy J. N., Wang S., Chang C. H., Elliott C. F., Xu Z., et al. (2019). Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. Jama 321, 2003&#x2013;2017. doi:&#xa0; 10.1001/jama.2019.5791, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.5791</ArticleId><ArticleId IdType="pmc">PMC6537818</ArticleId><ArticleId IdType="pubmed">31104070</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah F. A., Meyer N. J., Angus D. C., Awdish R., Azoulay &#xc9;., Calfee C. S., et al. (2021). A research agenda for precision medicine in sepsis and acute respiratory distress syndrome: an official American thoracic society research statement. Am. J. Respir. Crit. Care Med. 204, 891&#x2013;901. doi:&#xa0; 10.1164/rccm.202108-1908ST, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202108-1908ST</ArticleId><ArticleId IdType="pmc">PMC8534611</ArticleId><ArticleId IdType="pubmed">34652268</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah A., Smith A. F. (2020). Trial sequential analysis: adding a new dimension to meta-analysis. Anaesthesia 75, 15&#x2013;20. doi:&#xa0; 10.1111/anae.14705, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/anae.14705</ArticleId><ArticleId IdType="pubmed">31106849</ArticleId></ArticleIdList></Reference><Reference><Citation>Shehadeh F., Benitez G., Mylona E. K., Tran Q. L., Tsikala-Vafea M., Atalla E., et al. (2022). A pilot trial of thymalfasin (T&#x3b1;1) to treat hospitalized patients with hypoxemia and lymphocytopenia due to COVID-19 infection. J. Infect. Dis. 227 (2), 226&#x2013;235. doi:&#xa0; 10.1093/infdis/jiac362, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac362</ArticleId><ArticleId IdType="pmc">PMC9494344</ArticleId><ArticleId IdType="pubmed">36056913</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer M., Deutschman C. S., Seymour C. W., Shankar-Hari M., Annane D., Bauer M., et al. (2016). The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315, 801&#x2013;810. doi:&#xa0; 10.1001/jama.2016.0287, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.0287</ArticleId><ArticleId IdType="pmc">PMC4968574</ArticleId><ArticleId IdType="pubmed">26903338</ArticleId></ArticleIdList></Reference><Reference><Citation>Slim M. A., van Mourik N., Bakkerus L., Fuller K., Acharya L., Giannidis T., et al. (2024). Towards personalized medicine: a scoping review of immunotherapy in sepsis. Crit. Care 28, 183. doi:&#xa0; 10.1186/s13054-024-04964-6, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-024-04964-6</ArticleId><ArticleId IdType="pmc">PMC11134696</ArticleId><ArticleId IdType="pubmed">38807151</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne J. A., Sutton A. J., Ioannidis J. P., Terrin N., Jones D. R., Lau J., et al. (2011). Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. Bmj 343, d4002. doi:&#xa0; 10.1136/bmj.d4002, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d4002</ArticleId><ArticleId IdType="pubmed">21784880</ArticleId></ArticleIdList></Reference><Reference><Citation>Stortz J. A., Murphy T. J., Raymond S. L., Mira J. C., Ungaro R., Dirain M. L., et al. (2018). Evidence for persistent immune suppression in patients who develop chronic critical illness after sepsis. Shock 49, 249&#x2013;258. doi:&#xa0; 10.1097/SHK.0000000000000981, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000981</ArticleId><ArticleId IdType="pmc">PMC5809297</ArticleId><ArticleId IdType="pubmed">28885387</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y., Yao J., Ma Y., Zhang P., Zhou X., Xie W., et al. (2025). Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis. Front. Immunol. 16. doi:&#xa0; 10.3389/fimmu.2025.1571456, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2025.1571456</ArticleId><ArticleId IdType="pmc">PMC12208829</ArticleId><ArticleId IdType="pubmed">40599771</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres L. K., Pickkers P., van der Poll T. (2022). Sepsis-induced immunosuppression. Annu. Rev. Physiol. 84, 157&#x2013;181. doi:&#xa0; 10.1146/annurev-physiol-061121-040214, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-physiol-061121-040214</ArticleId><ArticleId IdType="pubmed">34705481</ArticleId></ArticleIdList></Reference><Reference><Citation>Trevelin S. C., Carlos D., Beretta M., da Silva J. S., Cunha F. Q. (2017). Diabetes mellitus and sepsis: A challenging association. Shock 47, 276&#x2013;287. doi:&#xa0; 10.1097/shk.0000000000000778, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/shk.0000000000000778</ArticleId><ArticleId IdType="pubmed">27787406</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Poll T., van de Veerdonk F. L., Scicluna B. P., Netea M. G. (2017). The immunopathology of sepsis and potential therapeutic targets. Nat. Rev. Immunol. 17, 407&#x2013;420. doi:&#xa0; 10.1038/nri.2017.36, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2017.36</ArticleId><ArticleId IdType="pubmed">28436424</ArticleId></ArticleIdList></Reference><Reference><Citation>Venet F., Monneret G. (2018). Advances in the understanding and treatment of sepsis-induced immunosuppression. Nat. Rev. Nephrol. 14, 121&#x2013;137. doi:&#xa0; 10.1038/nrneph.2017.165, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneph.2017.165</ArticleId><ArticleId IdType="pubmed">29225343</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallach J. D., Sullivan P. G., Trepanowski J. F., Sainani K. L., Steyerberg E. W., Ioannidis J. P. (2017). Evaluation of evidence of statistical support and corroboration of subgroup claims in randomized clinical trials. JAMA Intern. Med. 177, 554&#x2013;560. doi:&#xa0; 10.1001/jamainternmed.2016.9125, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2016.9125</ArticleId><ArticleId IdType="pmc">PMC6657347</ArticleId><ArticleId IdType="pubmed">28192563</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F. Y., Fang B., Qiang X. H., Yu T. O., Zhong J. R., Cao J., et al. (2016). The efficacy and immunomodulatory effects of ulinastatin and thymosin &#x3b1;1 for sepsis: A systematic review and meta-analysis. BioMed. Res. Int. 2016, 9508493. doi:&#xa0; 10.1155/2016/9508493, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/9508493</ArticleId><ArticleId IdType="pmc">PMC4906180</ArticleId><ArticleId IdType="pubmed">27340674</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J., Fang Q. (2004). Immune regulation mechanism of thymosin - &#x3b1;1 on severe sepsis patients. Chin. J. Crit. Care Med. 11), 39&#x2013;40. doi:&#xa0; 10.3969/j.issn.1002-1949.2004.11.015</Citation><ArticleIdList><ArticleId IdType="doi">10.3969/j.issn.1002-1949.2004.11.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J., Pei F., Zhou L., Li W., Sun R., Li Y., et al. (2025). The efficacy and safety of thymosin &#x3b1;1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. Bmj 388, e082583. doi:&#xa0; 10.1136/bmj-2024-082583, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2024-082583</ArticleId><ArticleId IdType="pmc">PMC11780596</ArticleId><ArticleId IdType="pubmed">39814420</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J., Tang Z., Chen J., Ouyang B., Chen M., Guan X. (2014). Changes of TLR2, TLR4 and MyD88 mRNA expressions on peripheral blood mononuclear cell in severe sepsis patients during treatment with Thymosin &#x3b1;1. Chin. Arch. Gen. Surg (Electronic Edition) 8, 270&#x2013;274. doi:&#xa0; 10.3877/cma.j.issn.1674-0793.2014.04.004</Citation><ArticleIdList><ArticleId IdType="doi">10.3877/cma.j.issn.1674-0793.2014.04.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J., Zhou L., Liu J., Ma G., Kou Q., He Z., et al. (2013). The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit. Care 17, R8. doi:&#xa0; 10.1186/cc11932, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc11932</ArticleId><ArticleId IdType="pmc">PMC4056079</ArticleId><ArticleId IdType="pubmed">23327199</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Q., Ma M., Zhang X., Deng M., Yang Y. (2015). Effect of acupuncture on prognosis and immune function of sepsis patients. Chin. J. Integrated Tradit Western Med. 35, 783&#x2013;786. doi:&#xa0; 10.7661/CJIM.2015.07.0783, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.7661/CJIM.2015.07.0783</ArticleId><ArticleId IdType="pubmed">26380438</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H., Yu Q., Ye X. (2018). Effect of thymosin on apoptosis and clinical efficacy of peripheral blood lymphocytes in patients with sepsis. Jiangxi Med. J. 53, 670&#x2013;673. doi:&#xa0; 10.3969/j.issn.1006-2238.2018.7.006</Citation><ArticleIdList><ArticleId IdType="doi">10.3969/j.issn.1006-2238.2018.7.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu K., He J., Wu Y., Xie B., Liu X., Wei B., et al. (2020). Dysregulated adaptive immune response contributes to severe COVID-19. Cell Res. 30, 814&#x2013;816. doi:&#xa0; 10.1038/s41422-020-0391-9, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-0391-9</ArticleId><ArticleId IdType="pmc">PMC7403569</ArticleId><ArticleId IdType="pubmed">32759967</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Dong N., Yao Y. (2024). Optimal strategy for treatment of sepsis based on the host inflammatory reaction and immune response. J. Intensive Med. 4, 175&#x2013;180. doi:&#xa0; 10.1016/j.jointm.2023.10.002, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jointm.2023.10.002</ArticleId><ArticleId IdType="pmc">PMC11043630</ArticleId><ArticleId IdType="pubmed">38681784</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y., Ley S. H., Hu F. B. (2018). Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat. Rev. Endocrinol. 14, 88&#x2013;98. doi:&#xa0; 10.1038/nrendo.2017.151, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrendo.2017.151</ArticleId><ArticleId IdType="pubmed">29219149</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou B., Perel P., Mensah G. A., Ezzati M. (2021). Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat. Rev. Cardiol. 18, 785&#x2013;802. doi:&#xa0; 10.1038/s41569-021-00559-8, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-021-00559-8</ArticleId><ArticleId IdType="pmc">PMC8162166</ArticleId><ArticleId IdType="pubmed">34050340</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L., Tan J., Li Y., Luo H., Shao Y., Qiang X., et al. (2009). Immue and inflammation confusion in severe sepsis and effects of bi-immunomodulation therapy: a prospective, randomized, controlled clinical trial. J. Chin. Med. 89, 1028&#x2013;1033. doi:&#xa0; 10.3760/cma.j.issn.0376-2491.2009.15.006, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.0376-2491.2009.15.006</ArticleId><ArticleId IdType="pubmed">19595251</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>